Clover Biopharmaceuticals
Research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies.
Launch date
Employees
Market cap
CAD44.4m
Enterprise valuation
(CAD33m) (Public information from Sep 2024)
Share price
HKD0.225 2197.HK
Chengdu Sichuan (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 39.3m | 15.9b | 18.5b |
| % growth | - | - | - | - | - | 40474 % | 16 % |
| EBITDA | (35.9m) | (904m) | (6.0b) | (2.4b) | 1.7b | 366m | 474m |
| % EBITDA margin | - | - | - | - | 4369 % | 2 % | 3 % |
| Profit | (48.6m) | (913m) | (6.0b) | (2.5b) | (139m) | - | - |
| % profit margin | - | - | - | - | (353 %) | - | - |
| EV / revenue | - | - | - | - | 7.9x | -0.1x | -0.1x |
| EV / EBITDA | - | - | -1.7x | -0.7x | 0.2x | -4.1x | -3.9x |
| R&D budget | 45.8m | 228m | 1.8b | 1.5b | 650m | - | - |
| R&D % of revenue | - | - | - | - | 1656 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | JPY62.8m | Series A | |
$43.3m | Series B | ||
* | N/A | Acquisition | |
$24.0m | Series B | ||
$230m | Series C | ||
| N/A | $260m | IPO | |
* | $38.9m | Grant | |
| Total Funding | CAD459m | ||
Related Content
Recent News about Clover Biopharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.